Economic Impact of the Application of a Precision Medicine Model (5SPM) on Psychotic Patients
Lorena Carrascal-Laso,1 Manuel Ángel Franco-Martín,1 Elena Marcos-Vadillo,2 Ignacio Ramos-Gallego,3 Belén García-Berrocal,2 Eduardo Mayor-Toranzo,1 Santiago Sánchez-Iglesias,4 Carolina Lorenzo,4 Alfonso Sevillano-Jiménez,1 Almudena Sánchez-Martín,5 María Jesús García-Salgado,2 María Isidoro-García2,...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2021-08-01
|
| Series: | Pharmacogenomics and Personalized Medicine |
| Subjects: | |
| Online Access: | https://www.dovepress.com/economic-impact-of-the-application-of-a-precision-medicine-model-5spm--peer-reviewed-fulltext-article-PGPM |
| _version_ | 1818612378897481728 |
|---|---|
| author | Carrascal-Laso L Franco-Martín M Marcos-Vadillo E Ramos-Gallego I García-Berrocal B Mayor-Toranzo E Sánchez-Iglesias S Lorenzo C Sevillano-Jiménez A Sánchez-Martín A García-Salgado MJ Isidoro-García M |
| author_facet | Carrascal-Laso L Franco-Martín M Marcos-Vadillo E Ramos-Gallego I García-Berrocal B Mayor-Toranzo E Sánchez-Iglesias S Lorenzo C Sevillano-Jiménez A Sánchez-Martín A García-Salgado MJ Isidoro-García M |
| author_sort | Carrascal-Laso L |
| collection | DOAJ |
| description | Lorena Carrascal-Laso,1 Manuel Ángel Franco-Martín,1 Elena Marcos-Vadillo,2 Ignacio Ramos-Gallego,3 Belén García-Berrocal,2 Eduardo Mayor-Toranzo,1 Santiago Sánchez-Iglesias,4 Carolina Lorenzo,4 Alfonso Sevillano-Jiménez,1 Almudena Sánchez-Martín,5 María Jesús García-Salgado,2 María Isidoro-García2,6 1Servicio de Psiquiatría, Hospital Provincial de Zamora, IBSAL, Zamora, 49071, Spain; 2Farmacogenética y Medicina de Precisión, Servicio de Bioquímica, Hospital Universitario de Salamanca, IBSAL, Salamanca, 37007, Spain; 3Departamento de Fisiología y Farmacología, Universidad de Salamanca, Salamanca, 37007, Spain; 4Servicio de Psiquiatría, Hospital Universitario de Salamanca, IBSAL, Salamanca, 37007, Spain; 5Pharmacogenetics Unit, Pharmacy Department, University Hospital Virgen de las Nieves, UGC Provincial de Farmacia de Granada, Granada, 18014, Spain; 6Departamento de Medicina, Universidad de Salamanca, Salamanca, 37007, SpainCorrespondence: Manuel Ángel Franco-Martín Email mfrancom@saludcastillayleon.esBackground: Schizophrenia is a severe mental disorder that often manifests within the first three decades of life. Its prognosis is uncertain and may result in a prolonged treatment that could extend throughout the entire lifespan of the patient. Antipsychotic drugs are characterized by a high interindividual variability when considering therapeutic effect and emergence of adverse effects. Such interindividual variability is thought to be associated primarily with pharmacokinetic matters.Objective: The objective of this study was to evaluate the economic impact of the application of the 5-Step Precision Medicine model (5SPM), an approach based on the pharmacogenetic analysis of the primary genes involved in the metabolism of the therapy for each patient, restructuring treatment as necessary.Patients and Methods: One hundred eighty-eight psychiatry patients were analysed for single nucleotide polymorphisms on genes CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A5 and ABCB1. Information on patients’ diagnosis, pharmacotherapy, and hospitalizations was collected.Results: We achieved a cost–benefit ratio of 3.31– 3.59 with a reduction of direct cost (hospitalizations plus pharmacotherapy) with a reduction of total cost in 67% of the patients who underwent the clinical intervention.Conclusion: A rational Precision Medicine-based approach to psychiatric patients could result in a reduction on number of drugs required to control exacerbations, and the underlying pathologies, reducing the risk of adverse effects and improving adherence to treatment, leading to a potential decrease in direct costs. This methodology has been shown to be cost-dominant and, being based on a pharmacogenetic analysis, it has a lifelong nature, as the data obtained can be applied to other medical disciplines.Keywords: pharmacogenetics, pharmacoeconomics, psychotic disorders, cytochrome P-450, antipsychotics |
| first_indexed | 2024-12-16T15:45:17Z |
| format | Article |
| id | doaj.art-d9dc98e647f544fe86235e0270451bcf |
| institution | Directory Open Access Journal |
| issn | 1178-7066 |
| language | English |
| last_indexed | 2024-12-16T15:45:17Z |
| publishDate | 2021-08-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Pharmacogenomics and Personalized Medicine |
| spelling | doaj.art-d9dc98e647f544fe86235e0270451bcf2022-12-21T22:25:49ZengDove Medical PressPharmacogenomics and Personalized Medicine1178-70662021-08-01Volume 141015102567959Economic Impact of the Application of a Precision Medicine Model (5SPM) on Psychotic PatientsCarrascal-Laso LFranco-Martín MMarcos-Vadillo ERamos-Gallego IGarcía-Berrocal BMayor-Toranzo ESánchez-Iglesias SLorenzo CSevillano-Jiménez ASánchez-Martín AGarcía-Salgado MJIsidoro-García MLorena Carrascal-Laso,1 Manuel Ángel Franco-Martín,1 Elena Marcos-Vadillo,2 Ignacio Ramos-Gallego,3 Belén García-Berrocal,2 Eduardo Mayor-Toranzo,1 Santiago Sánchez-Iglesias,4 Carolina Lorenzo,4 Alfonso Sevillano-Jiménez,1 Almudena Sánchez-Martín,5 María Jesús García-Salgado,2 María Isidoro-García2,6 1Servicio de Psiquiatría, Hospital Provincial de Zamora, IBSAL, Zamora, 49071, Spain; 2Farmacogenética y Medicina de Precisión, Servicio de Bioquímica, Hospital Universitario de Salamanca, IBSAL, Salamanca, 37007, Spain; 3Departamento de Fisiología y Farmacología, Universidad de Salamanca, Salamanca, 37007, Spain; 4Servicio de Psiquiatría, Hospital Universitario de Salamanca, IBSAL, Salamanca, 37007, Spain; 5Pharmacogenetics Unit, Pharmacy Department, University Hospital Virgen de las Nieves, UGC Provincial de Farmacia de Granada, Granada, 18014, Spain; 6Departamento de Medicina, Universidad de Salamanca, Salamanca, 37007, SpainCorrespondence: Manuel Ángel Franco-Martín Email mfrancom@saludcastillayleon.esBackground: Schizophrenia is a severe mental disorder that often manifests within the first three decades of life. Its prognosis is uncertain and may result in a prolonged treatment that could extend throughout the entire lifespan of the patient. Antipsychotic drugs are characterized by a high interindividual variability when considering therapeutic effect and emergence of adverse effects. Such interindividual variability is thought to be associated primarily with pharmacokinetic matters.Objective: The objective of this study was to evaluate the economic impact of the application of the 5-Step Precision Medicine model (5SPM), an approach based on the pharmacogenetic analysis of the primary genes involved in the metabolism of the therapy for each patient, restructuring treatment as necessary.Patients and Methods: One hundred eighty-eight psychiatry patients were analysed for single nucleotide polymorphisms on genes CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A5 and ABCB1. Information on patients’ diagnosis, pharmacotherapy, and hospitalizations was collected.Results: We achieved a cost–benefit ratio of 3.31– 3.59 with a reduction of direct cost (hospitalizations plus pharmacotherapy) with a reduction of total cost in 67% of the patients who underwent the clinical intervention.Conclusion: A rational Precision Medicine-based approach to psychiatric patients could result in a reduction on number of drugs required to control exacerbations, and the underlying pathologies, reducing the risk of adverse effects and improving adherence to treatment, leading to a potential decrease in direct costs. This methodology has been shown to be cost-dominant and, being based on a pharmacogenetic analysis, it has a lifelong nature, as the data obtained can be applied to other medical disciplines.Keywords: pharmacogenetics, pharmacoeconomics, psychotic disorders, cytochrome P-450, antipsychoticshttps://www.dovepress.com/economic-impact-of-the-application-of-a-precision-medicine-model-5spm--peer-reviewed-fulltext-article-PGPMpharmacogeneticspharmacoeconomicspsychotic disorderscytochrome p-450antipsychotics |
| spellingShingle | Carrascal-Laso L Franco-Martín M Marcos-Vadillo E Ramos-Gallego I García-Berrocal B Mayor-Toranzo E Sánchez-Iglesias S Lorenzo C Sevillano-Jiménez A Sánchez-Martín A García-Salgado MJ Isidoro-García M Economic Impact of the Application of a Precision Medicine Model (5SPM) on Psychotic Patients Pharmacogenomics and Personalized Medicine pharmacogenetics pharmacoeconomics psychotic disorders cytochrome p-450 antipsychotics |
| title | Economic Impact of the Application of a Precision Medicine Model (5SPM) on Psychotic Patients |
| title_full | Economic Impact of the Application of a Precision Medicine Model (5SPM) on Psychotic Patients |
| title_fullStr | Economic Impact of the Application of a Precision Medicine Model (5SPM) on Psychotic Patients |
| title_full_unstemmed | Economic Impact of the Application of a Precision Medicine Model (5SPM) on Psychotic Patients |
| title_short | Economic Impact of the Application of a Precision Medicine Model (5SPM) on Psychotic Patients |
| title_sort | economic impact of the application of a precision medicine model 5spm on psychotic patients |
| topic | pharmacogenetics pharmacoeconomics psychotic disorders cytochrome p-450 antipsychotics |
| url | https://www.dovepress.com/economic-impact-of-the-application-of-a-precision-medicine-model-5spm--peer-reviewed-fulltext-article-PGPM |
| work_keys_str_mv | AT carrascallasol economicimpactoftheapplicationofaprecisionmedicinemodel5spmonpsychoticpatients AT francomartinm economicimpactoftheapplicationofaprecisionmedicinemodel5spmonpsychoticpatients AT marcosvadilloe economicimpactoftheapplicationofaprecisionmedicinemodel5spmonpsychoticpatients AT ramosgallegoi economicimpactoftheapplicationofaprecisionmedicinemodel5spmonpsychoticpatients AT garciaberrocalb economicimpactoftheapplicationofaprecisionmedicinemodel5spmonpsychoticpatients AT mayortoranzoe economicimpactoftheapplicationofaprecisionmedicinemodel5spmonpsychoticpatients AT sancheziglesiass economicimpactoftheapplicationofaprecisionmedicinemodel5spmonpsychoticpatients AT lorenzoc economicimpactoftheapplicationofaprecisionmedicinemodel5spmonpsychoticpatients AT sevillanojimeneza economicimpactoftheapplicationofaprecisionmedicinemodel5spmonpsychoticpatients AT sanchezmartina economicimpactoftheapplicationofaprecisionmedicinemodel5spmonpsychoticpatients AT garciasalgadomj economicimpactoftheapplicationofaprecisionmedicinemodel5spmonpsychoticpatients AT isidorogarciam economicimpactoftheapplicationofaprecisionmedicinemodel5spmonpsychoticpatients |